Rajesh Chopra
Io Therapeutics (United States)(US)ESIC Hospital(IN)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Ubiquitin and proteasome pathways
Most-Cited Works
- → Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial(1993)1,044 cited
- → Challenges to curing primary brain tumours(2019)952 cited
- → Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study(2006)834 cited
- → Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS(2015)821 cited
- → Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide(2012)790 cited
- → Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN(2013)615 cited